
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES51

The main differences across all the different treatment groups were:
  the high frequency of gastrointestinal (GI) complaints reported by metformin-treated
patients
  the high frequency of hypoglycaemic events reported by sulfonylurea-treated patients
  the high number of episodes of oedema reported by glitazone-treated patients
  the high number of cases of upper respiratory infection in patients treated with
meglitinides.
Level 1+

[@Unkown_date]

[@Schernthaner_2004]

[@Bailey_2005]

[@Marre_2002]

[@Kvapil_2006]

[@Fujioka_2003]

